Dear Investors,
We cordially invite you to participate in WuXi AppTec2022 interim results conference call, thank you for your interest in WuXi AppTec, and we look forward to your participation.
•Conference will be held in Beijing time2022year7month27am8:00-8:50Convocation
>
Dear Investors,
WuXi AppTec is pleased to invite you to our 1H22 Earnings Call. We thank you for your interest and we sincerely hope you will join us.< /p>
• Earnings Call at 8:00-8:50 a.m., July 27, China time (8:00-8:50
p.m., July 26, EST)
About WuXi PharmaTech WuXi AppTec (stock code: 603259.SH/2359.HK) provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, and North America. Through its unique “CRDMO” and “CTDMO” business models, WuXi AppTec continuously lowers the R&D threshold, helps customers improve R&D efficiency, and brings more breakthrough treatment solutions to patients. The service scope covers chemical drug R&D and production, biological Research, preclinical testing and clinical trial development, cell and gene therapy development, testing and production. In 2021, WuXi AppTec will be rated AA for ESG (Environmental, Social and Governance) by MSCI. At present, the company’s empowerment platform is carrying the R&D and innovation projects of more than 5,800 partners from more than 30 countries around the world. medicine, incurable disease” vision. About WuXi AppTecAs a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,800 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”